Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cymbalta Clear all
Recruiting Not applicable Interventional

The Treatment of Painful Diabetic Neuropathy With Diet

NCT07509671
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Peripheral Neuropathy With Type 2 Diabetes, Vegan Diet
Interventions
Diet, Medical management
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Hendersonville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain

NCT01912612
View directory record Official record
Conditions
Pain
Interventions
Duloxetine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
25 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 4 Interventional

A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression

NCT00296699
View directory record Official record
Conditions
Atypical Depression
Interventions
Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 30, 2026, 9:47 PM EDT
Terminated Phase 4 Interventional Results available

Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction

NCT00398632
View directory record Official record
Conditions
Depression
Interventions
Duloxetine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Results available

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

NCT02260388
View directory record Official record
Conditions
Cryptogenic Sensory Polyneuropathy
Interventions
Nortriptyline, Duloxetine, Pregabalin, Mexiletine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

NCT00321490
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 3 Interventional

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

NCT00190866
View directory record Official record
Conditions
Fibromyalgia
Interventions
Duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
33
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

NCT00385671
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride, pregabalin, gabapentin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Torrance, California • Cromwell, Connecticut • Staten Island, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate ), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Carson, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Not applicable Interventional Results available

Brain Morphometry in OA Patients Treated With Duloxetine

NCT02903238
View directory record Official record
Conditions
Pain, Osteoarthritis
Interventions
Duloxetine, Placebo Oral Tablet
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine for Multiple Sclerosis Pain

NCT00755807
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Duloxetine Hydrochloride (HCI), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Duloxetine RCT on Postop TKA Outcomes

NCT05086393
View directory record Official record
Conditions
Pain, Postoperative, Total Knee Arthroplasty
Interventions
Duloxetine, Placebos
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Exercise Plus Duloxetine for Knee Osteoarthritis

NCT04111627
View directory record Official record
Conditions
Knee Osteoarthritis, Depression
Interventions
Aerobic exercise, Duloxetine
Behavioral · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 4 Interventional

The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment

NCT02590874
View directory record Official record
Conditions
Mild Cognitive Impairment, Depression
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Duloxetine on Norepinephrine

NCT00414323
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Escitalopram, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Glendale, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Oct 30, 2026, 9:47 PM EDT
Recruiting No phase listed Observational

Measuring Analgesic Interventions

NCT03794362
View directory record Official record
Conditions
Pain
Interventions
Not listed
Lead sponsor
Julia Finkel
Other
Eligibility
7 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Neuromuscular Fatigue Post Stroke

NCT01688570
View directory record Official record
Conditions
Stroke
Interventions
duloxetine, Cyproheptadine, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Treatment on Decision-making in Major Depression

NCT01916824
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Controls
Interventions
Any FDA Approved Antidepressant
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 30, 2026, 9:47 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

NCT05120934
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG, Duloxetine 60 MG, Placebo 30 MG, Placebo 60 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

A Study for Patient With Chronic Low Back Pain

NCT00767806
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Chandler, Arizona • Cromwell, Connecticut • DeLand, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microbiome Derived Metabolism and Pharmacokinetics

NCT05065671
View directory record Official record
Conditions
Microbial Colonization
Interventions
Tolcapone 100 MG, Duloxetine 20 MG
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 9:47 PM EDT
Completed Phase 2Phase 3 Interventional

Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression

NCT00215228
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine vs. escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 30, 2026, 9:47 PM EDT